{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:14:57Z","timestamp":1793193297551,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Medical Research Center, Korea Science and Engineering Foundation, Republic of Korea","award":["R13-2002-005-04001-0"],"award-info":[{"award-number":["R13-2002-005-04001-0"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.pnpbp.2010.12.003","type":"journal-article","created":{"date-parts":[[2010,12,12]],"date-time":"2010-12-12T04:04:58Z","timestamp":1292126698000},"page":"490-496","source":"Crossref","is-referenced-by-count":32,"title":["A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone"],"prefix":"10.1016","volume":"35","author":[{"given":"Seung-Yup","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin A.","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Un","family":"Pae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2010.12.003_bb0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4088\/JCP.v60n0402","article-title":"The distribution of body mass index among individuals with and without schizophrenia","volume":"60","author":"Allison","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ps.54.4.565","article-title":"The impact of weight gain on quality of life among persons with schizophrenia","volume":"54","author":"Allison","year":"2003","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.psychres.2008.10.007","article-title":"Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean?","volume":"170","author":"Allison","year":"2009","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","author":"American Diabetes Association APA","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.schres.2008.10.023","article-title":"Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients","volume":"108","author":"Bai","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.014","article-title":"Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study","volume":"111","author":"Bai","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0269881107075509","article-title":"Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia","volume":"21","author":"Barnett","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-9964(02)00431-0","article-title":"Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study","volume":"62","author":"Bobes","year":"2003","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2010.02.1030","article-title":"Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort","volume":"119","author":"Bobes","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0055","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.schres.2009.09.024","article-title":"Biochemical risk factors for development of obesity in first-episode schizophrenia","volume":"115","author":"Boden","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0060","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/schbul\/sbp065","article-title":"Predictors of outcome in brief cognitive behavior therapy for schizophrenia","volume":"35","author":"Brabban","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.schres.2007.10.005","article-title":"Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950\u20132005","volume":"98","author":"Capasso","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0070","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.cger.2007.06.001","article-title":"The anorexia of aging","volume":"23","author":"Chapman","year":"2007","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0075","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.schres.2006.07.025","article-title":"Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE","volume":"88","author":"De Hert","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0085","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0165-1781(01)00234-7","article-title":"Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate","volume":"101","author":"Fontaine","year":"2001","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0090","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/08039480701414932","article-title":"Mortality among persons with schizophrenia in Sweden: an epidemiological study","volume":"61","author":"Fors","year":"2007","journal-title":"Nord J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0095","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course","volume":"43","author":"Gebhardt","year":"2009","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0100","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0163-8343(00)00081-5","article-title":"Weight gain from novel antipsychotic drugs: need for action","volume":"22","author":"Green","year":"2000","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0105","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/ajcn\/82.5.941","article-title":"Factors influencing variation in basal metabolic rate include fat-free mass, fat mass, age, and circulating thyroxine but not sex, circulating leptin, or triiodothyronine","volume":"82","author":"Johnstone","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0110","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0115","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4088\/JCP.v64n0921f","article-title":"Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine","volume":"64","author":"Kelly","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0120","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.pra.0000358319.81307.a5","article-title":"Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation","volume":"15","author":"Khan","year":"2009","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0125","first-page":"CD006654","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","volume":"3","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0130","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archpsyc.59.11.1021","article-title":"An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients","volume":"59","author":"Koro","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0135","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/bmj.325.7358.243","article-title":"Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study","volume":"325","author":"Koro","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2009.02.006","article-title":"Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol","volume":"110","author":"Krakowski","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0145","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0899-9007(01)00555-X","article-title":"Fat-free and fat mass percentiles in 5225 healthy subjects aged 15 to 98years","volume":"17","author":"Kyle","year":"2001","journal-title":"Nutrition"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0150","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/ejcn.2009.1","article-title":"Longitudinal changes in energy expenditure in an elderly German population: a 12-year follow-up","volume":"63","author":"Luhrmann","year":"2009","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arr.2009.08.002","article-title":"Energy expenditure and aging","volume":"9","author":"Manini","year":"2010","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0160","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/cap.2000.10.259","article-title":"Risperidone-associated weight gain in children and adolescents: a retrospective chart review","volume":"10","author":"Martin","year":"2000","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/10401230600801168","article-title":"A retrospective study of weight changes and the contributing factors in short term adult psychiatric inpatients","volume":"18","author":"Megna","year":"2006","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0170","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4088\/JCP.v63n0509","article-title":"A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1year","volume":"63","author":"Meyer","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4088\/JCP.v59n0205","article-title":"The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics","volume":"59","author":"Miller","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0180","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0010-440X(96)90054-1","article-title":"Diabetes mellitus in schizophrenic patients","volume":"37","author":"Mukherjee","year":"1996","journal-title":"Compr Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.pnpbp.2010.12.003_bb0185","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0190","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4088\/JCP.08m04132","article-title":"A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone","volume":"70","author":"Newcomer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/070674379103600401","article-title":"Mortality in a cohort of patients with schizophrenia: a record linkage study","volume":"36","author":"Newman","year":"1991","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.schres.2010.02.1061","article-title":"Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study","volume":"119","author":"Okumura","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0205","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/bmj.321.7259.483","article-title":"Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study","volume":"321","author":"Osby","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0210","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e318172b8e6","article-title":"Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1year of treatment","volume":"28","author":"Perez-Iglesias","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0215","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","article-title":"Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study","volume":"41","author":"Ratzoni","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0220","first-page":"6","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"6","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0225","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.lfs.2003.08.044","article-title":"The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia","volume":"74","author":"Ryan","year":"2004","journal-title":"Life Sci"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/jcp.0b013e3181602fe6","article-title":"Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol","volume":"28","author":"Saddichha","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0235","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.jcp.0000130558.86125.5b","article-title":"A comparison of risperidone-induced weight gain across the age span","volume":"24","author":"Safer","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0240","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0245","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"Simon","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0250","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","article-title":"Second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis","volume":"192","author":"Smith","year":"2008","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0255","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2007.02.024","article-title":"Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis","volume":"93","author":"Strassnig","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0260","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4088\/JCP.v68n0711","article-title":"Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey","volume":"68","author":"Suvisaari","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0265","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00406-007-0762-y","article-title":"Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey","volume":"258","author":"Suvisaari","year":"2008","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0270","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2125.2007.02852.x","article-title":"Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia","volume":"64","author":"Tang","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0275","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1192\/bjp.184.47.s76","article-title":"Metabolic disturbance in first-episode schizophrenia","volume":"47","author":"Thakore","year":"2004","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0280","doi-asserted-by":"crossref","first-page":"997","DOI":"10.4088\/JCP.08m04508","article-title":"Metabolic risk factors in drug-naive patients with first-episode psychosis","volume":"70","author":"Verma","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0285","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/schbul\/sbp016","article-title":"Substance use disorders in schizophrenia-clinical implications of comorbidity","volume":"35","author":"Volkow","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0290","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance","volume":"66","author":"Weiden","year":"2004","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0295","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.jcp.0000185427.08268.db","article-title":"Effects of age and sex on olanzapine plasma concentrations","volume":"25","author":"Weiss","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.12.003_bb0300","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1055\/s-2003-814853","article-title":"Bodyweight in inpatients with schizophrenia","volume":"31","author":"Wetterling","year":"2004","journal-title":"Psychiatr Prax"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610004744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610004744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T21:39:47Z","timestamp":1559857187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584610004744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0278584610004744"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2010.12.003","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}